Herceptin Trastuzumab
Trademark details
Herceptin Trastuzumab® is a registered trademark used for Providing Information On the Subject of Medical Conditions and Therapies Via a Global Computer Network and owned by Genentech, Inc.. Full trade mark registration details, registered images and more information below.
| Goods and/or Services: | Providing Information On the Subject of Medical Conditions and Therapies Via a Global Computer Network |
| Serial Number: | 78894574 |
| Filing Date: | May 26, 2006 |
|
Last Applicant(s)/ Owner(s) of Record | Genentech, Inc.1 Dna Way |
| Related Products: | Medical services; Veterinary services; Hygienic and beauty care for humans or animals |
Suppliers
Total : 1 View more »
Genentech, Inc. in Sacramento, California, USA
Edit this Company edit this company Genentech, Inc. 980 9th St Ste 2180 Sacramento, California 95814-2716 USA tel: +1 9164435703 http://www.gene.com...
Web Sites
powered by 
Total : 460,000 View more »
HER2+ Breast Cancer Treatment with Herceptin® (trastuzumab)
Herceptin® (trastuzumab) is a HER2+ breast cancer therapy designed to treat aggressive HER positive metastatic and adjuvant breast cancer. BREAST CANCER INDICATIONS ...
Trastuzumab - Wikipedia, the free encyclopedia
Trastuzumab (INN ; trade name Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers. The HER ...
Trastuzumab - National Cancer Institute - Comprehensive Cancer ...
US Brand Name(s): Herceptin: FDA Approved: Yes ... Trastuzumab is also being studied in the treatment of other types of cancer.
Trastuzumab, Herceptin - Chemotherapy Drugs, Chemo Drug Side Effects
Trastuzumab is the generic name for the trade name chemotherapy drug Herceptin. Trastuzumab is a monoclonal antibody used for treating metastatic breast cancer.
Web Sites
Total : 12 View more »
In Vitro Companion Diagnostic Devices
...cancer patients for whom Herceptin (Trastuzumab) therapy is being considered...assessment of patients for whom Herceptin (trastuzumab) treatment is being considered...assessment of patients for whom Herceptin (trastuzumab) treatment is being considered...
doi:10.1016/S0140-6736(05)66712-8
...available for advanced breast cancer via the UK NHS. “I think it would be far more sensible to prescribe Herceptin [trastuzumab] sooner rather than later, when in the later stages it can only prolong life by a few months”, she told the...
ROCHE-layoutV2.indd
A pan-European comparison regarding patient access to cancer drugs Nils Wilking Bengt Jönsson Karolinska Institutet in collaboration with Stockholm School of Economics Stockholm, Sweden Foreword One of the great triumphs of scientific research has been to advance our knowledge of the causes and
Herceptin Now Approved In The EU For Patients With HER2-Positive Metastatic Gastric Cancer — Irish
...Share herceptin_package_1_image1_1 Roche wish to announce that the European Commission has approved Herceptin (trastuzumab) in combination with capecitabine or 5-fluorouracil and cisplatin for use in patients with HER2-positive...
News and Blogs
Total : 82 View more »
Galena Biopharma With Near Term ASCO Catalyst - Seeking Alpha
...those with HER2 3+ disease are eligible for Herceptin® (trastuzumab; Roche-Genentech (RHHBY.PK)) which had...II trial comparing NeuVax in combination with Herceptin (trastuzumab) versus trastuzumab alone, in a 300-patient...
Roche announces positive phase 2 results for trastuzumab emtansine | Pharma Asia
...phase 2 trial, known as TDM4450g, compared trastuzumab emtansine (T-DM1) single agent to the combination of Herceptin (trastuzumab) and chemotherapy (docetaxel) in previously untreated patients. The results showed that patients treated...
Stomach Cancer-Drug Pipeline Analysis and Market Forecasts to 2016
...Assessment 10 3.3 Product Profiles of Major Marketed Drugs in the Stomach Cancer Market 11 3.3.1 Herceptin (trastuzumab) 11 3.3.2 Taxotere (docetaxel) 12 3.3.3 Xeloda 14 3.3.4 Gleevec (imatinib) 15 ...
News: YM Biosciences Claims Collaboration with Canada’s NRC-BRI Yielded Novel Anticancer Antibodies.
...new HER2 antibodies. The partners claim that these candidates could be safer than existing antibody-based drugs such Herceptin® (trastuzumab; Genentech/Roche). The new candidates have been designed to bind to HER2/neu on cancer cells but...
